Article Text

Download PDFPDF
Manipulation of the gut–liver axis by interruption of bile acid recirculation: an option for the treatment of sclerosing cholangitis?
  1. Daniel Jahn1,
  2. Marco Marzioni2,
  3. Andreas Geier1
  1. 1 Division of Hepatology, Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
  2. 2 Clinic of Gastroenterology and Hepatology, Università Politecnica delle Marche, Ospedali Riuniti University Hospital, Ancona, Italy
  1. Correspondence to Dr Andreas Geier, Division of Hepatology, University Hospital Würzburg, Würzburg D-97080, Germany; Geier_A2{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Patients affected by primary sclerosing cholangitis (PSC) have a dramatically increased risk to develop end-stage liver disease and cholangiocarcinoma. Medical treatment options for PSC are currently limited and often liver transplantation remains inevitable. This demonstrates the urgent need for novel pharmacological treatment strategies that are safe and efficient.

Bile acid (BA) sequestrants are resins that bind to BAs in the intestinal lumen, thereby decreasing their intestinal re-uptake and interrupting their enterohepatic circulation. Resins have a longstanding use in the treatment of BA-induced diarrhoea and cholestatic pruritus. However, only a very limited number of studies have so far investigated the therapeutic impact of BA sequestrants on the underlying cholestatic liver disease.

In Gut, Fuchs et al present an experimental study investigating the effects of the BA sequestrant colesevelam on cholestatic liver disease in the Mdr2−/− mouse model of sclerosing cholangitis.1 Using this model, the authors convincingly show that colesevelam efficiently treats the clinically relevant liver phenotype including inflammation, tissue damage, fibrosis and efficiently normalised serum liver enzymes. With regard to the underlying mechanisms, the study clearly shows that colesevelam profoundly alters BA homeostasis. This is demonstrated by a marked increase of the total faecal BA output together with a nearly complete loss of the intestinal fibroblast growth factor (FGF) 15 expression and a concomitant increase of hepatic de novo BA synthesis. Interestingly, the increased synthesis apparently even overcompensates the faecal BA loss, since colesevelam-treated Mdr2−/− animals had an increased hepatic and biliary BA pool size compared with untreated controls. However, there is also a profound impact of colesevelam on BA pool …

View Full Text


  • MM and AG share senior authorship

  • Contributors DJ and AG created the first draft of the manuscript. All authors discussed the general outline of the manuscript; reviewed, edited and approved the final version of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests DJ: nothing to disclose. MM: nothing to disclose. AG advises for AbbVie, Alexion, BMS, Gilead, Intercept, Novartis, and Sequana, is on the speakers’ bureau for AbbVie, Alexion, BMS, Falk, Gilead, Intercept, Novartis and Sequana, and received research grants from Intercept and Novartis.

  • Patient consent Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles